Antiviral Drugs - Chad

Chad

The projected revenue of the Antiviral Drugs market in Chad is expected to reach US$1.50m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 1.17%, leading to a market volume of US$1.59m by 2029.
In comparison to other countries worldwide, United States is projected to generate the highest revenue in the market, amounting to US$30,640.00m in 2024.
Chad's market for antiviral drugs is experiencing significant growth due to the rising prevalence of infectious diseases in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand in Chad due to the prevalence of viral diseases such as HIV/AIDS, hepatitis, and influenza. The Antiviral Drugs market in Chad has witnessed a steady growth in recent years, driven by various factors.

Customer preferences: Chadian customers prefer affordable and accessible antiviral drugs that are effective in treating viral diseases. Due to the low purchasing power of the population, many customers opt for generic antiviral drugs over branded ones. Additionally, customers tend to purchase antiviral drugs from local pharmacies rather than hospitals or clinics.

Trends in the market: The Antiviral Drugs market in Chad has witnessed a trend towards the development of combination therapies. Combination therapies involve the use of two or more antiviral drugs to treat viral diseases. This approach has been effective in reducing the development of drug resistance and improving treatment outcomes. Another trend in the market is the increasing use of antiviral drugs for prophylaxis or prevention of viral diseases.

Local special circumstances: Chad has a high prevalence of viral diseases such as HIV/AIDS and hepatitis. According to the World Health Organization (WHO), approximately 1.4% of the adult population in Chad is living with HIV/AIDS. The government has implemented various programs to combat the spread of these diseases, including the distribution of antiviral drugs. However, the lack of healthcare infrastructure and trained personnel has resulted in limited access to antiviral drugs in some areas.

Underlying macroeconomic factors: Chad is one of the poorest countries in the world, with a GDP per capita of less than $700. The low purchasing power of the population has resulted in limited access to healthcare, including antiviral drugs. Additionally, the country is heavily dependent on oil exports, which makes it vulnerable to fluctuations in oil prices. The COVID-19 pandemic has also had a significant impact on the economy, leading to a decline in government revenues and increased healthcare spending.In conclusion, the Antiviral Drugs market in Chad is developing due to the high prevalence of viral diseases, customer preferences for affordable and accessible drugs, and the trend towards combination therapies. However, limited access to healthcare infrastructure and trained personnel, as well as underlying macroeconomic factors, pose challenges to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.